Alpha 2.0
Login Register
» Authors » Miklos Diossy

Miklos Diossy

Explore the profile of Miklos Diossy including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 298
Followers 0
Related Specialties
Oncology
General Medicine
Molecular Biology
Top 10 Co-Authors
Zoltan Szallasi
Zsofia Sztupinszki
Judit Borcsok
Istvan Csabai
Viktoria Tisza
Sandor Spisak
Aurel Prosz
Pranshu Sahgal
Marcin Krzystanek
Orsolya Rusz
Published In
NPJ Precis Oncol
Clin Cancer Res
Nat Med
NPJ Breast Cancer
bioRxiv
Affiliations
Soon will be listed here.
Recent Articles
11.
Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer
Sztupinszki Z, Diossy M, Borcsok J, Prosz A, Cornelius N, Kjeldsen M, et al.
Clin Cancer Res . 2021 Aug; 27(20):5681-5687. PMID: 34380641
Purpose: Homologous recombination (HR) deficiency (HRD) is one of the key determinants of PARP inhibitor response in ovarian cancer, and its accurate detection in tumor biopsies is expected to improve...
12.
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures
Diossy M, Sztupinszki Z, Borcsok J, Krzystanek M, Tisza V, Spisak S, et al.
NPJ Precis Oncol . 2021 Jun; 5(1):55. PMID: 34145376
PARP inhibitors are approved for the treatment of solid tumor types that frequently harbor alterations in the key homologous recombination (HR) genes, BRCA1/2. Other tumor types, such as lung cancer,...
13.
Strand Orientation Bias Detector to determine the probability of FFPE sequencing artifacts
Diossy M, Sztupinszki Z, Krzystanek M, Borcsok J, Eklund A, Csabai I, et al.
Brief Bioinform . 2021 May; 22(6). PMID: 34015811
Formalin-fixed paraffin-embedded tissue, the most common tissue specimen stored in clinical practice, presents challenges in the analysis due to formalin-induced artifacts. Here, we present Strand Orientation Bias Detector (SOBDetector), a...
14.
Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer
Borcsok J, Diossy M, Sztupinszki Z, Prosz A, Tisza V, Spisak S, et al.
Clin Cancer Res . 2021 May; 27(13):3734-3743. PMID: 33947694
Purpose: Poly (ADP ribose)-polymerase (PARP) inhibitors are approved for use in breast, ovarian, prostate, and pancreatic cancers, which are the solid tumor types that most frequently have alterations in key...
15.
Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer
Borcsok J, Sztupinszki Z, Bekele R, Gao S, Diossy M, Samant A, et al.
Clin Cancer Res . 2020 Nov; 27(7):2011-2022. PMID: 33208343
Purpose: Cisplatin-based chemotherapy is a first-line treatment for muscle-invasive and metastatic urothelial cancer. Approximately 10% of bladder urothelial tumors have a somatic missense mutation in the nucleotide excision repair (NER)...
16.
Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations
Sztupinszki Z, Diossy M, Krzystanek M, Borcsok J, Pomerantz M, Tisza V, et al.
Clin Cancer Res . 2020 Feb; 26(11):2673-2680. PMID: 32071115
Purpose: Prostate cancers with mutations in genes involved in homologous recombination (HR), most commonly BRCA2, respond favorably to PARP inhibition and platinum-based chemotherapy. We investigated whether other prostate tumors that...
17.
Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer
Sztupinszki Z, Diossy M, Krzystanek M, Reiniger L, Csabai I, Favero F, et al.
NPJ Breast Cancer . 2018 Jul; 4:16. PMID: 29978035
The first genomic scar-based homologous recombination deficiency (HRD) measures were produced using SNP arrays. As array-based technology has been largely replaced by next generation sequencing approaches, it has become important...